Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1726 • 2015 ACR/ARHP Annual Meeting
Reliability of Radiographic Assessment of Psoriatic Arthritis Mutilans
Dennis Wong¹, Ker-Ai Lee², Richard J. Cook³, Dafna Gladman⁴, Lihi Eder⁴ and Vinod Chandran⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis mutilans (PsAM) is the most severe form of Psoriatic arthritis (PsA). Research on PsAM has been hampered by the lack of an…
Abstract Number: 103 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis
Deepak R. Jadon¹, John Bowes², Anne Barton³, Raj Sengupta¹, Alison L Nightingale⁴, Mark Lindsay⁵, Eleanor Korendowych¹, Graham Robinson⁶ and Neil J. McHugh⁷, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁴Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁶Royal United Hospital, Bath, United Kingdom, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: A lack of well-characterised clinical cohorts has impeded research of the genetics of axial disease in psoriatic arthritis (PsA). We sought to determine genetic…
Abstract Number: 2495 • 2015 ACR/ARHP Annual Meeting
Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis
Alexander Langer¹ and Hans-Eckhard Langer², ¹Department of Computer Science, RWTH Aachen University, Aachen, Germany, ²RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany
Background/Purpose: There is evidence that tight control of rheumatoid arthritis improves outcome. In daily practice this aim is constricted by logistic limitations such as a…
Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…
Abstract Number: 2839 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Christopher J. Edwards¹, Francisco J. Blanco², Jeffrey Crowley³, ChiaChi Hu⁴, Kamal Shah⁴ and Charles A. Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Warren, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
Abstract Number: 2843 • 2015 ACR/ARHP Annual Meeting
Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephen Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, Kamal Shah⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁸University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated clear efficacy and good tolerability in psoriatic arthritis (PsA) and psoriasis. Longer term data are…
Abstract Number: 1963 • 2014 ACR/ARHP Annual Meeting
Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis
Siba Raychaudhuri¹, Anupam Mitra², Ananya Datta Mitra³, Christine Abria⁴ and Smriti K. Raychaudhuri³, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Research, VA Sacramento Medical Center, Mather, CA
Background/Purpose: The PI3K/Akt/mTOR signaling proteins are pro-growth/pro-survival and thus likely to regulate inflammatory cascades in autoimmune diseases (1). The key pathologic outcome in psoriatic arthritis…
Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Anna Cooper¹, Johan A. Karlsson² and Anders Gülfe¹, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
Abstract Number: 1853 • 2014 ACR/ARHP Annual Meeting
Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Philip J. Mease¹, David Collier², Chitra Karki³, Guo Li⁴, Bojena Bitman⁵ and Jeffrey D. Greenberg^3,6, ¹Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Amgen, Inc., San Francisco, CA, ⁶Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Registry data regarding biologic DMARD therapy as a mono or combo (combined with a traditional oral DMARD) in subjects with Psoriatic Arthritis (PsA) are…
Abstract Number: 953 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert Landewé⁷, Peter Nash⁸, Luminita Pricop⁹, Jiacheng Yuan¹⁰, Hanno Richards¹¹ and Shephard Mpofu¹², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁸University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies. We present the first randomized, multicenter, double-blind,…
Abstract Number: 1597 • 2014 ACR/ARHP Annual Meeting
Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Frank Zhang¹, Thomas Tencer¹, Stan Li² and Vibeke Strand³, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²Celgene Corporation, Warren, NJ, ³Biopharmaceutical Consultant, Portola Valley, CA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the aberrant immune response that causes the joint symptoms, systemic inflammation, and skin…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)
Saedis Saevarsdottir¹, Michele Santacatterina², Carl Turesson³, Helena Forsblad⁴, Lennart Jacobsson⁴ and Staffan Lindblad⁵, ¹Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁴Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁵Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
Abstract Number: 955 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial
Peter Schafer¹, Peng Chen², Lorraine Fang², Andrew Wang² and Rajesh Chopra³, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Biostatistics, Celgene Corporation, Warren, NJ, ³Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].